Role of baseline soluble tumor necrosis factor receptor 2 as a biomarker in primary podocytopathy: Implications for renal impairment and disease progression

Srinivas Nagaram,Priscilla Charles,Yadav Nisha,Norton Stephen,Nandeesha Hanumanthappa,Sreejith Parameswaran,Palanivel Chinnakali,Rajesh Nachiappa Ganesh
DOI: https://doi.org/10.1186/s12882-024-03772-y
2024-10-26
BMC Nephrology
Abstract:Podocytopathies, including minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and collapsing glomerulopathy (CG), are kidney diseases that damage glomerular podocytes, leading to heavy proteinuria and nephrotic syndrome (NS). Inflammation plays a critical role in the progression of chronic kidney disease (CKD), with recent studies linking inflammatory biomarkers to declining kidney function. Tumor necrosis factor-alpha (TNF-α), an essential inflammatory cytokine, interacts with its circulating receptors, TNFR1 and TNFR2. The TNF-α pathway has been implicated in the pathogenesis of FSGS and MCD. Increased circulating TNFR2 levels have been associated with worsening renal function in podocytopathies, suggesting that the TNF-α inflammatory pathway significantly contributes to disease progression.
urology & nephrology
What problem does this paper attempt to address?